CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer
Dong Hoon Lee, Jung Ho Kim, Won Ik Seo, Jong Kil Nam, Tae Nam Kim, Cheol Kyu Oh, Soo Dong Kim, Sung-Woo Park, Jae Sung Chung, Sang Hyun Park, Wan Lee, Gyung Tak Sung, Moon Kee Chung, Jae Il Chung
Korean J Urol Oncol. 2017;15(2):59-65.   Published online 2017 August 29    DOI: https://doi.org/10.22465/kjuo.2017.15.2.59

Excel Download

Intermittent Chemotherapy with Docetaxel for Metastatic Castration-Resistant Prostate Cancer
Hormone Therapy and Castration Resistance of Prostate Cancer. 2018;357-368   Crossref logo
Link1

Metabolic Health for Patients with Prostate Cancer During Androgen Deprivation Therapy
Hormone Therapy and Castration Resistance of Prostate Cancer. 2018;151-164   Crossref logo
Link1

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
Prostate International. 2015;3(4):123-126   Crossref logo
Link1 Link2

Androgen Deprivation Therapy for Clinically Localized Prostate Cancer
Hormone Therapy and Castration Resistance of Prostate Cancer. 2018;121-131   Crossref logo
Link1

MP53-06 THE EFFECTIVE PERIOD OF FIRST ANDROGEN DEPRIVATION THERAPY BECOMES AN PROGNOSTIC THE EFFECTIVE PERIOD OF FIRST ANDROGEN-DEPRIVATION THERAPY BECOMES AN PROGNOSTIC FACTOR IN DOCETAXEL CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Journal of Urology. 2017;197(4S):   Crossref logo
Link1 Link2

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
Clinical Genitourinary Cancer. 2018;16(2):130-134   Crossref logo
Link1 Link2

Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration
International Journal of Clinical Oncology. 2019;24(5):546-553   Crossref logo
Link1 Link2 Link3

Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer
The Korean Journal of Urological Oncology. 2017;15(2):59-65   Crossref logo
Link1 Link2 Link3

Economic Evaluation of Abiraterone in Metastatic Castration-Resistant Prostate Cancer in Patients With None/Mild Symptoms After Failure of Androgen Deprivation Therapy
Value in Health. 2017;20(9):A446   Crossref logo
Link1 Link2

Chemotherapy and Androgen Receptor-Directed Treatment of Castration Resistant Metastatic Prostate Cancer
Management of Prostate Cancer. 2017;327-342   Crossref logo
Link1